Table 3.
30-Day and 2-year clinical outcomes after TAVR in patients treated vs. not treated with ACEI/ARB
| ACEI/ARB treatment (n = 1736) | No ACEI/ARB treatment (n = 2243) | P-value | |
|---|---|---|---|
| 30-Day | |||
| All-cause death | 2.3 (40) | 3.2 (71) | 0.10 |
| Cardiovascular | 1.8 (32) | 2.5 (56) | 0.16 |
| Non-cardiovascular | 0.5 (8) | 0.7 (15) | 0.38 |
| Disabling stroke | 2.0 (34) | 2.1 (46) | 0.83 |
| Death or disabling stroke | 3.9 (67) | 4.8 (107) | 0.16 |
| Myocardial infarction | 1.3 (23) | 1.2 (27) | 0.74 |
| Periprocedural | 0.8 (14) | 0.9 (20) | 0.77 |
| Major vascular complicationsa | 7.1 (123) | 7.5 (167) | 0.66 |
| Life threatening or disabling bleedinga | 5.8 (101) | 7.1 (160) | 0.09 |
| Acute kidney injurya | 18.8 (265) | 17.8 (326) | 0.36 |
| New permanent pacemaker | 10.8 (187) | 10.1 (224) | 0.45 |
| 2-Year | |||
| All-cause death | 18.6 (316) | 27.5 (606) | <0.0001 |
| Cardiovascular | 12.3 (203) | 17.9 (378) | <0.0001 |
| Non-cardiovascular | 7.2 (113) | 11.7 (228) | <0.0001 |
Values are % (n).
a
According to VARC 2 definition.